New Horizons in Severe Asthma

Program Overview

For this Interactive Showcase™ in severe asthma (SA), grab your mobile device and headphones for a unique journey through several engaging educational experiences. The first activity, designed as an expert-guided poster tour, will briefly review the underlying mechanisms of SA. Subsequently, you will attend a live expert roundtable where faculty will discuss evolving management approaches, including the use of newer agents that target inflammatory mediators of disease. During the final activity you will participate in interactive case studies, applying information acquired to real-time management decisions. You don’t want to miss this!

Target Audience

The educational design of this activity addresses the needs of clinical immunologists/allergists, pulmonologists, and other specialist clinicians involved in the treatment of patients with severe asthma.

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe key pathophysiologic processes in severe asthma development and persistence, including the roles of thymic stromal lymphopoietin (TSLP) and implications for treatment
• Discuss the clinical profiles and recent trial results with newer biologic therapies for severe asthma
• Construct biologic-based treatment regimens for patients with severe asthma to maximize asthma control, prevent exacerbations, and incorporate shared clinical decision making

Faculty

Monica Kraft, MD
System Chair, Samuel Bronfman Department of Medicine
Murray M. Rosenberg Professor of Medicine
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York

Erika Gonzalez, MD
Chief Executive Officer and President
South Texas Allergy & Asthma Medical Professionals (STAAMP)
STAAMP Clinical Research
Adjunct Clinical Professor in Internal Medicine
The University of Texas Health Science Center at San Antonio
San Antonio, Texas

Jonathan Corren, MD
Clinical Faculty
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Sanofi S.A.; Honoraria: Chiesi USA, Inc.

Erika Gonzalez, MD: Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, Teva Pharmaceutical Industries Ltd.

Jonathan Corren, MD: Consulting Fee: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: Amgen, Inc., AstraZeneca plc, Novartis Pharmaceuticals Corporation, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd.; Speakers Bureau: Amgen, Inc., AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The Integritas planners and managers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.